HOME >> MEDICINE >> NEWS
Enoxaparin beats unfractionated heparin as adjunct therapy for heart attacks

cardial Infraction. (ExTRACT-TIMI 25) study led by the TIMI Study Group (Boston).

"Based on the results of the ExTRACT-TIMI 25 trial, we believe that a strategy using enoxaparin is now the preferred anticoagulant regimen in heart attack patients who receive clot-busting drugs," said Eugene Braunwald, M.D., M.A.C.C., Distinguished Hersey Professor of Medicine, Harvard Medical School, Chairman, TIMI Study Group, Brigham and Women's Hospital.

Researchers found that enoxaparin reduced the combined risk of death and MI within 30 days by 17 percent. Similarly, enoxaparin reduced the 30-day risk of nonfatal repeat MI by 33 percent, and the 30-day combined risk of death, nonfatal MI, and urgent need to re-establish blood flow to the heart by 19 percent. All of the findings were highly statistically significant.

The trial enrolled 20,506 patients from 674 medical centers in 48 countries. All patients had ST-elevation MI (STEMI), a serious form of heart attack characterized by elevation of the "ST segment" on the electrocardiogram. They were treated with a fibrinolytic, or clot-busting, medication within six hours of first experiencing chest pain, and were then randomly assigned to receive therapy with enoxaparin or unfractionated heparin.

To make sure there was no unintended bias in interpreting the results, the trial used a double-blind, double-dummy design: study participants received both intravenous infusions and twice-daily injections without the physician or the patient knowing which contained the study medication and which was the placebo.

The rates of serious bleeding were lower overall than reported in prior trials. Patients who were treated with the enoxaparin strategy were more likely to experience major bleeding. However, when researchers calculated net clinical benefit, which takes into account both effectiveness and safety, the enoxaparin strategy was, on balance, associated with significantly better outcomes.
'"/>


14-Mar-2006


Page: 1 2 3

Related medicine news :

1. US beats Europe for hypertension treatment
2. For super-obese patients, duodenal switch beats gastric bypass
3. Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
4. New data demonstrate effectiveness of LAMICTAL (lamotrigine) as adjunctive therapy
5. Chemotherapy with bevacizumab increases risk of blood clots in arteries
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
8. Hormone therapy offers new hope for ovarian cancer patients
9. Borderline personality disorder shows improvements with intensive psychotherapy
10. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
(Date:8/4/2015)... ... 04, 2015 , ... Nathan’s Famous was recently featured on NewsWatch ... large businesses making an impact in their industry. Andrew Tropeano, the host of NewsWatch ... hot dog maker now offers a 50% Reduced Fat All-Beef Frank variety and ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... Winscribe Text results have been impressive so far". , Mr Cauchois attributes ... from Winscribe's French sales partner Dicma and the healthcare technology offered by Winscribe's ...
(Date:8/3/2015)... ... August 04, 2015 , ... While the pace of the economic recovery since the ... clearly been on a growth trajectory for the last six years. Unemployment has dropped from ... trending at a 3.5 percent growth rate in 2014, the U.S. stock market is at ...
(Date:8/3/2015)... ... 03, 2015 , ... Zeiter’s Septic now performs septic installations ... and operated business, Zeiter’s Septic has been serving the community for over 20 ... because of their continued training and perseverance to provide their customers with new ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Code ... the T500 cable , a Bluetooth Code Reader accessory that enables a wireless ... products. The T500 helps enable a variety of barcode reading applications with iPads, ...
Breaking Medicine News(10 mins):Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3
(Date:8/3/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" or the ... HZNP ) ("Horizon") announcement that it intends to request ... record date to determine the shareholders eligible to request ... will review the request when it is received. Provided ... information required under Depomed,s bylaws, the Depomed Board will, ...
(Date:8/3/2015)... 3, 2015 Cooperative ... military surgical research and top-tier universities for ... to severe wound treatments for critical-care patients ... medicine and tissue-engineered skin substitute advancements.  Biotech ... in focus are Amarantus Bioscience Holdings, Inc. ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
Breaking Medicine Technology:Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6
Cached News: